- Home
- XYF vs MREO Comparison
XYF vs MREO Comparison
Compare XYF & MREO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- XYF
- MREO
- Stock Information
- Founded
- XYF 2014
- MREO 2015
- Country
- XYF China
- MREO United Kingdom
- Employees
- XYF N/A
- MREO N/A
- Industry
- XYF Finance: Consumer Services
- MREO Biotechnology: Pharmaceutical Preparations
- Sector
- XYF Finance
- MREO Health Care
- Exchange
- XYF Nasdaq
- MREO Nasdaq
- Market Cap
- XYF 582.9M
- MREO 369.2M
- IPO Year
- XYF 2018
- MREO N/A
- Fundamental
- Price
- XYF $13.41
- MREO $2.42
- Analyst Decision
- XYF
- MREO Strong Buy
- Analyst Count
- XYF 0
- MREO 7
- Target Price
- XYF N/A
- MREO $7.71
- AVG Volume (30 Days)
- XYF 130.5K
- MREO 1.5M
- Earning Date
- XYF 05-29-2025
- MREO 05-19-2025
- Dividend Yield
- XYF 2.68%
- MREO N/A
- EPS Growth
- XYF 28.68
- MREO N/A
- EPS
- XYF 4.32
- MREO N/A
- Revenue
- XYF $804,452,842.00
- MREO N/A
- Revenue This Year
- XYF N/A
- MREO N/A
- Revenue Next Year
- XYF N/A
- MREO $56.11
- P/E Ratio
- XYF $2.98
- MREO N/A
- Revenue Growth
- XYF 21.95
- MREO N/A
- 52 Week Low
- XYF $3.68
- MREO $1.58
- 52 Week High
- XYF $17.70
- MREO $5.02
- Technical
- Relative Strength Index (RSI)
- XYF 52.84
- MREO 50.79
- Support Level
- XYF $12.50
- MREO $2.28
- Resistance Level
- XYF $14.45
- MREO $2.75
- Average True Range (ATR)
- XYF 1.00
- MREO 0.16
- MACD
- XYF -0.02
- MREO 0.00
- Stochastic Oscillator
- XYF 71.80
- MREO 32.65
About XYF X Financial each representing six
X Financial is a Cayman Islands-based technology-driven personal finance company. Along with its subsidiaries, the firm provides diversified investment opportunities to investors in China through its wealth management platform, Xiaoying Wealth Management. Loan products offered by the company include Xiaoying Card Loan, Xiaoying Preferred Loan, and Xiaoying Housing Loan. The company generates revenue from loan facilitation service, post-origination service, and guarantee services provided.
About MREO Mereo BioPharma Group plc
Mereo BioPharma Group PLC is a United Kingdom (U.K.) based biopharmaceutical company focused on the development of innovative therapeutics for rare diseases. The Company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat primarily for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD).